Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
The Globe and Mail20h
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
The company's collaboration partner, Vertex Pharmaceuticals(NASDAQ: VRTX), made progress activating authorized treatment centers capable of administrating Casgevy, but CRISPR still hasn't reported any ...
sicklecellanemianews21h
Orna, Vertex partner on gene-editing therapies for SCD, TDT
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price ...